In glioblastoma, BCL6 represents a key downstream target of MED12, with the increased BCL6 protein able to suppress TP53-mediated apoptosis [107], while it lies downstream of KRAS in lung cancer [108]. This evidence concerns the gene BCL6 and lung cancer.